PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference

Fani, Melpomeni; Del Pozzo, Luigi; Abiraj, Keelara; Mansi, Rosalba; Tamma, Maria Luisa; Cescato, Renzo; Waser, Beatrice; Weber, Wolfgang A; Reubi, Jean Claude; Maecke, Helmut R (2011). PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. Journal of nuclear medicine, 52(7), pp. 1110-8. New York, N.Y.: Society of Nuclear Medicine 10.2967/jnumed.111.087999

Full text not available from this repository. (Request a copy)

Somatostatin-based radiolabeled peptides have been successfully introduced into the clinic for targeted imaging and radionuclide therapy of somatostatin receptor (sst)-positive tumors, especially of subtype 2 (sst2). The clinically used peptides are exclusively agonists. Recently, we showed that radiolabeled antagonists may be preferable to agonists because they showed better pharmacokinetics, including higher tumor uptake. Factors determining the performance of radioantagonists have only scarcely been studied. Here, we report on the development and evaluation of four (64)Cu or (68)Ga radioantagonists for PET of sst2-positive tumors.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Cescato, Renzo; Waser, Beatrice and Reubi, Jean-Claude

ISSN:

0161-5505

Publisher:

Society of Nuclear Medicine

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:18

Last Modified:

17 Mar 2015 19:23

Publisher DOI:

10.2967/jnumed.111.087999

PubMed ID:

21680701

Web of Science ID:

000292297900017

URI:

https://boris.unibe.ch/id/eprint/5556 (FactScience: 210310)

Actions (login required)

Edit item Edit item
Provide Feedback